Clinical Trials
269 trialsEACH
University College, London
Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery
M.D. Anderson Cancer Center
Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
TORERO
Gustave Roussy, Cancer Campus, Grand Paris
Radiotherapy in Association With Cetuximab in Patients Treated for an Epidermoid Cancer
Centre Oscar Lambret
DARTBOARD
University of Texas Southwestern Medical Center
Palbociclib and Cetuximab in Metastatic Colorectal Cancer
UNC Lineberger Comprehensive Cancer Center
CIML NK Cell in Head & Neck Cancer
Dana-Farber Cancer Institute
A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma
Memorial Sloan Kettering Cancer Center
Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer
Institut du Cancer de Montpellier - Val d'Aurelle
Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck
Yale University
Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
University of California, San Diego
A PHASE IB STUDY OF IMMUNOTHERAPY WITH EX VIVO PRE-ACTIVATED AND EXPANDED CB-NK CELLS IN COMBINATION WITH CETUXIMAB, IN COLORECTAL CANCER PATIENTS WITH MINIMAL RESIDUAL DISEASE (MRD)
M.D. Anderson Cancer Center
Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
FCR-VADS
Institut Bergonié
CETUXICOL
Institut Curie
NeoBRAF
AIO-Studien-gGmbH
AACER
Centre Antoine Lacassagne
Efficacy and Safety of Triweekly Cetuximab in Combination With Capecitabine as First-line Maintenance Treatment for KRAS/BRAF Wild-type Metastatic Colorectal Cancer
Sun Yat-sen University
ECHO-07
GERCOR - Multidisciplinary Oncology Cooperative Group
SAMCO
Federation Francophone de Cancerologie Digestive
NIVOTAX
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Case Review of Patients With Betel Nut-induced Oral Cancer Treated With Pembrolizumab and Cetuximab
Commonwealth Healthcare Corporation
MoLiMoR - A Study With FOLFIRI-based First-line Therapy With or Without Intermittent Cetuximab
TheraOp
Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma
Memorial Sloan Kettering Cancer Center
Paclitaxel Plus Cetuximab After First-line Checkpoint Inhibitor Failure
Medical University of Vienna
A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment
NuCana plc
AIO-KRK-0114
Ludwig-Maximilians - University of Munich
FOLFIRI + Cetuximab + Avelumab RAS Wild-type CRC
Ludwig-Maximilians - University of Munich
sEphB4-HSA With RT+Chemo or Cetux in Patients With Intermediate to High Risk LAHNSCC
University of Colorado, Denver
ITACa
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
AVETRIC
Gruppo Oncologico del Nord-Ovest
APA
Washington University School of Medicine
Induction Chemotherapy Followed by Chemoradiation With Cetuximab in Head and Neck Cancer
Institute of Oncology Ljubljana
SULTAN
UNICANCER
Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma
University of Arizona
Cabozantinib in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer
Memorial Sloan Kettering Cancer Center
Post-operative Radiation With Cetuximab for Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck
University of Cincinnati
Bevacizumab/Ph 2 for Locally Advanced Head and Neck Cancer
The University of Texas Health Science Center at San Antonio
ELAN-UNFIT
Gustave Roussy, Cancer Campus, Grand Paris
Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Stanford University
PD 0332991 and Cetuximab in Patients With Incurable SCCHN
Washington University School of Medicine
Cetuximab Before Surgery in Treating Patients With Aggressive Locally Advanced Skin Cancer
Rutgers, The State University of New Jersey
AFACET
The Netherlands Cancer Institute
ESTER
Institut du Cancer de Montpellier - Val d'Aurelle
SBRT With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated SCCHN
University of Pittsburgh
Study of Anti-Epidermal Growth Factor Receptor (EGFr) Antibody, Cetuximab, in Combination With Gemcitabine/Carboplatin in Patients With Stage IV Lung Cancer
University of Alabama at Birmingham
Temsirolimus (CCI-770, Torisel) Combined With Cetuximab in Cetuximab-Refractory Colorectal Cancer
Massachusetts General Hospital
Cetuximab in Head and Neck Cancer Patients
University of Wisconsin, Madison
PembroRad
Groupe Oncologie Radiotherapie Tete et Cou